Literature DB >> 30605986

[Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (Edition 2018)].

.   

Abstract

Entities:  

Keywords:  Diagnosis; Guidelines; Lung neoplasms; Therapy

Mesh：

Year:  2018        PMID： 30605986     DOI： 10.3760/cma.j.issn.0253-3766.2018.12.012

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN： 0253-3766


× No keyword cloud information.
  14 in total

1.  Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China.

Authors:  Haijing Guan; Chunping Wang; Chen Chen; Sheng Han; Zhigang Zhao
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

2.  Expression of miR-92a, miR-224 and miR-25 in non-small cell lung cancer and their correlation with clinical characteristics.

Authors:  Hao Yuan; Jiajia Su; Siqin Hu; Peng Wei
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer.

Authors:  Jun Lu; Hua Zhong; Jun Wu; Tianqing Chu; Lele Zhang; Hua Li; Qiming Wang; Rong Li; Yizhuo Zhao; Aiqin Gu; Huimin Wang; Chunlei Shi; Liwen Xiong; Xueyan Zhang; Wei Zhang; Yuqing Lou; Bo Yan; Yu Dong; Yanwei Zhang; Baolan Li; Li Zhang; Xiaodong Zhao; Kai Li; Baohui Han
Journal:  Adv Sci (Weinh)       Date:  2019-08-19       Impact factor: 16.806

4.  A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer.

Authors:  Zhihua Zhu; Zhengbo Song; Wenjie Jiao; Weijian Mei; Chunwei Xu; Qinghua Huang; Chaolun An; Jianguang Shi; Wenxian Wang; Guiping Yu; Pingli Sun; Yinbin Zhang; Jianfei Shen; Yong Song; Jun Qian; Wang Yao; Han Yang
Journal:  Transl Lung Cancer Res       Date:  2021-02

5.  A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer.

Authors:  Zhihua Zhu; Weijian Mei; Zhengbo Song; Wenjie Jiao; Qinghua Huang; Lianxin Zhu; Chaolun An; Jianguang Shi; Wenxian Wang; Guiping Yu; Pingli Sun; Yinbin Zhang; Jianfei Shen; Yong Song; Sebastien Gilbert; Kurt Ruetzler; Nestor R Villamizar; Chunwei Xu; Jun Qian; Wang Yao; Han Yang
Journal:  Transl Lung Cancer Res       Date:  2021-12

6.  Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma.

Authors:  Sixian Chen; Aizhen Fu; Yuan Lu; Wei Lu; Yongfeng Chen; Shuiqiang Hong; Suli Zhou; Tianmin Xiang; Zhenzhen Zhang; Yongguang Cai
Journal:  BMC Genomics       Date:  2022-01-15       Impact factor: 3.969

7.  Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China.

Authors:  Yafei Shi; Wei Chen; Yujun Zhang; Mingming Bo; Chunyu Li; Mingyu Zhang; Guohui Li
Journal:  Ann Transl Med       Date:  2021-09

8.  Ventilation in patients with stage IIIB or above lung cancer.

Authors:  Haiqin Zhang; Jinhua Ni; Qijian Cheng
Journal:  Ann Transl Med       Date:  2021-11

9.  Comorbidity in lung cancer patients and its association with medical service cost and treatment choice in China.

Authors:  Ruoxi Ding; Dawei Zhu; Ping He; Yong Ma; Zhishui Chen; Xuefeng Shi
Journal:  BMC Cancer       Date:  2020-03-24       Impact factor: 4.430

10.  Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy.

Authors:  Xianghua Zeng; Shicong Zhu; Cheng Xu; Zhongyu Wang; Xingxing Su; Dong Zeng; Haixia Long; Bo Zhu
Journal:  Med Sci Monit       Date:  2020-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.